Share This:
https://ntp.niehs.nih.gov/go/5933

TDMS Study 96007-05 Pathology Tables

NTP Experiment-Test: 96007-05         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03
Study Type: CHRONIC                             TOXIC EQUIVALENCY FACTOR EVALUATION(PECDF)                        Date: 09/30/03
Route: GAVAGE                                                                                                     Time: 11:22:49

                                                         FINAL #3/RATS




       Facility:  Battelle Columbus Laboratory

       Chemical CAS #:  57117-31-4

       Lock Date:  07/25/02

       Cage Range:  All

       Reasons For Removal:    25018 Dosing Accident                   25019 Moribund Sacrifice
                               25020 Natural Death                     25021 Terminal Sacrifice

       Removal Date Range:     All

       Treatment Groups:       Include All

































a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 96007-05         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                             TOXIC EQUIVALENCY FACTOR EVALUATION(PECDF)                        Date: 09/30/03    
Route: GAVAGE                                                                                                     Time: 11:22:49    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG/KG      6 NG/KG      20 NG/KG     44 NG/KG     92 NG/KG     200             
                                                                                                                    NG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially In Study                          98           98           98           98           98           98           
  Early Deaths                                                                                                                      
    Natural Death                                      7           10           10            8           14           11           
    Moribund Sacrifice                                21           20           17           19           19           19           
    Dosing Accident                                                 1            2            1                                     
  Survivors                                                                                                                         
    Terminal Sacrifice                                25           22           24           25           20           23           
                                                                                                                                    
  Animals Examined Microscopically                    53           53           53           53           53           53           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Esophagus                                          (53)         (53)         (52)         (53)         (53)         (53)         
      Cyst                                                                                    2 (4%)                                
      Perforation                                                   1 (2%)       2 (4%)       1 (2%)                                
      Muscularis, Inflammation                                      2 (4%)       1 (2%)       1 (2%)       1 (2%)       1 (2%)      
      Periesophageal Tissue, Inflammation                           1 (2%)       2 (4%)       2 (4%)       1 (2%)                   
   Intestine Large, Colon                             (53)         (53)         (53)         (53)         (51)         (53)         
      Edema                                                                                                1 (2%)                   
      Inflammation                                                                                         1 (2%)       1 (2%)      
      Parasite Metazoan                                2 (4%)                                                                       
   Intestine Large, Rectum                            (53)         (53)         (53)         (53)         (52)         (53)         
      Parasite Metazoan                                4 (8%)       5 (9%)       5 (9%)       1 (2%)       1 (2%)       1 (2%)      
      Artery, Inflammation, Chronic Active                          1 (2%)                    1 (2%)                                
   Intestine Large, Cecum                             (53)         (53)         (53)         (52)         (51)         (53)         
      Inflammation                                                                                         1 (2%)                   
      Artery, Inflammation, Chronic Active                          1 (2%)                                              2 (4%)      
      Artery, Mineralization                                                                               1 (2%)                   
   Intestine Small, Ileum                             (53)         (53)         (53)         (52)         (52)         (53)         
      Parasite Metazoan                                1 (2%)                                                                       
   Liver                                              (53)         (53)         (53)         (52)         (53)         (53)         
      Angiectasis                                      6 (11%)      3 (6%)       4 (8%)       1 (2%)                    1 (2%)      
      Basophilic Focus                                10 (19%)     11 (21%)      9 (17%)     10 (19%)     12 (23%)      6 (11%)     
      Basophilic Focus, Multiple                      12 (23%)     12 (23%)     11 (21%)      6 (12%)      3 (6%)       1 (2%)      
      Cholangiofibrosis                                             1 (2%)                    3 (6%)       3 (6%)       5 (9%)      
      Clear Cell Focus                                11 (21%)      1 (2%)       7 (13%)      2 (4%)                    3 (6%)      
      Clear Cell Focus, Multiple                       2 (4%)       5 (9%)       3 (6%)       1 (2%)       6 (11%)      8 (15%)     
      Degeneration, Cystic                                                                                              1 (2%)      
      Eosinophilic Focus                               7 (13%)     11 (21%)      9 (17%)      9 (17%)     11 (21%)     10 (19%)     
      Eosinophilic Focus, Multiple                     8 (15%)      2 (4%)       9 (17%)      9 (17%)     12 (23%)     18 (34%)     
      Fatty Change, Diffuse                            1 (2%)       4 (8%)      10 (19%)     12 (23%)     20 (38%)     26 (49%)     
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    2                                                              
                                                                                                                                   
NTP Experiment-Test: 96007-05         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                             TOXIC EQUIVALENCY FACTOR EVALUATION(PECDF)                        Date: 09/30/03    
Route: GAVAGE                                                                                                     Time: 11:22:49    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG/KG      6 NG/KG      20 NG/KG     44 NG/KG     92 NG/KG     200             
                                                                                                                    NG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
ALIMENTARY SYSTEM - CONT                                                                                                            
      Fatty Change, Focal                              5 (9%)       6 (11%)      5 (9%)       6 (12%)      6 (11%)      4 (8%)      
      Hematopoietic Cell Proliferation                24 (45%)     28 (53%)     27 (51%)     24 (46%)     39 (74%)     31 (58%)     
      Hemorrhage                                       1 (2%)                                                                       
      Hepatodiaphragmatic Nodule                       3 (6%)       3 (6%)       3 (6%)       1 (2%)       1 (2%)       1 (2%)      
      Hyperplasia, Nodular                                                                    3 (6%)       8 (15%)     12 (23%)     
      Inflammation                                    47 (89%)     44 (83%)     47 (89%)     50 (96%)     48 (91%)     50 (94%)     
      Mixed Cell Focus                                 5 (9%)                    1 (2%)       2 (4%)       2 (4%)       1 (2%)      
      Mixed Cell Focus, Multiple                      28 (53%)     24 (45%)     23 (43%)     27 (52%)     25 (47%)     25 (47%)     
      Necrosis                                         4 (8%)      10 (19%)      3 (6%)       3 (6%)       6 (11%)     18 (34%)     
      Pigmentation                                    13 (25%)     11 (21%)     21 (40%)     44 (85%)     42 (79%)     48 (91%)     
      Toxic Hepatopathy                                             2 (4%)       3 (6%)       8 (15%)     27 (51%)     44 (83%)     
      Artery, Inflammation, Chronic Active                                                                              1 (2%)      
      Bile Duct, Cyst                                  7 (13%)      4 (8%)       2 (4%)       3 (6%)       2 (4%)       7 (13%)     
      Bile Duct, Fibrosis                              1 (2%)       4 (8%)       2 (4%)       2 (4%)       3 (6%)       6 (11%)     
      Bile Duct, Hyperplasia                           3 (6%)       2 (4%)       2 (4%)       2 (4%)       1 (2%)      13 (25%)     
      Centrilobular, Degeneration                      4 (8%)       2 (4%)       3 (6%)       4 (8%)       4 (8%)       5 (9%)      
      Hepatocyte, Hypertrophy                          2 (4%)      13 (25%)     17 (32%)     17 (33%)     24 (45%)     34 (64%)     
      Hepatocyte, Multinucleated                                                 4 (8%)      13 (25%)     18 (34%)     35 (66%)     
      Oval Cell, Hyperplasia                           1 (2%)       4 (8%)       2 (4%)       6 (12%)     15 (28%)     35 (66%)     
      Portal, Fibrosis                                                                                                  1 (2%)      
   Mesentery                                          (1)          (2)          (1)          (3)          (2)          (4)          
      Inflammation                                                  1 (50%)                                                         
      Necrosis                                                                   1 (100%)                                           
      Artery, Inflammation, Chronic Active                          1 (50%)                   2 (67%)      1 (50%)      4 (100%)    
      Fat, Necrosis                                    1 (100%)                               1 (33%)      1 (50%)                  
   Oral Mucosa                                        (52)         (53)         (52)         (53)         (53)         (53)         
      Gingival, Cyst                                                                          1 (2%)                                
      Gingival, Hyperplasia                                                                   1 (2%)                                
      Gingival, Hyperplasia, Squamous                 15 (29%)     11 (21%)     16 (31%)     19 (36%)     22 (42%)     20 (38%)     
   Pancreas                                           (53)         (53)         (53)         (52)         (52)         (52)         
      Cyst                                                                                                 1 (2%)                   
      Cytoplasmic Alteration                                                                                            3 (6%)      
      Inflammation, Chronic Active                     2 (4%)       1 (2%)       1 (2%)       1 (2%)                    4 (8%)      
      Lipomatosis                                                                             1 (2%)                                
      Acinus, Atrophy                                  3 (6%)       1 (2%)       1 (2%)       1 (2%)                    3 (6%)      
      Acinus, Hyperplasia                                           1 (2%)                                                          
      Acinus, Vacuolization Cytoplasmic                                                                    2 (4%)      23 (44%)     
      Artery, Inflammation, Chronic Active             1 (2%)       2 (4%)       1 (2%)       2 (4%)       4 (8%)      11 (21%)     
      Duct, Dilatation                                                                                                  1 (2%)      
   Salivary Glands                                    (53)         (53)         (51)         (53)         (51)         (51)         
      Atrophy                                          1 (2%)                                                           2 (4%)      
      Duct, Inflammation                                            1 (2%)                                                          
   Stomach, Forestomach                               (53)         (53)         (53)         (53)         (52)         (53)         
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    3                                                              
                                                                                                                                   
NTP Experiment-Test: 96007-05         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                             TOXIC EQUIVALENCY FACTOR EVALUATION(PECDF)                        Date: 09/30/03    
Route: GAVAGE                                                                                                     Time: 11:22:49    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG/KG      6 NG/KG      20 NG/KG     44 NG/KG     92 NG/KG     200             
                                                                                                                    NG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
ALIMENTARY SYSTEM - CONT                                                                                                            
      Cyst                                                                                                              1 (2%)      
      Edema                                                         1 (2%)                                                          
      Hyperkeratosis                                                             1 (2%)                                             
      Hyperplasia, Squamous                            4 (8%)       1 (2%)       5 (9%)       6 (11%)      3 (6%)      10 (19%)     
      Inflammation                                     1 (2%)       1 (2%)                    2 (4%)       2 (4%)       2 (4%)      
      Mineralization                                                                          1 (2%)                                
      Ulcer                                                         1 (2%)       2 (4%)       2 (4%)       1 (2%)       1 (2%)      
      Artery, Inflammation, Chronic Active                                                                 1 (2%)       3 (6%)      
   Stomach, Glandular                                 (53)         (53)         (53)         (53)         (52)         (53)         
      Erosion                                                                    1 (2%)       2 (4%)       1 (2%)                   
      Hyperplasia                                                                             1 (2%)                                
      Inflammation                                     1 (2%)                                 1 (2%)                                
      Mineralization                                   2 (4%)       9 (17%)      1 (2%)       3 (6%)       2 (4%)       4 (8%)      
      Ulcer                                            1 (2%)                                                                       
      Artery, Inflammation, Chronic Active                                                                 1 (2%)       1 (2%)      
      Serosa, Inflammation                                          1 (2%)                                                          
   Tooth                                              (33)         (25)         (22)         (30)         (29)         (29)         
      Peridontal Tissue, Inflammation                 33 (100%)    25 (100%)    22 (100%)    30 (100%)    29 (100%)    29 (100%)    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Blood Vessel                                       (53)         (53)         (53)         (53)         (53)         (53)         
      Aorta, Mineralization                                         1 (2%)                    1 (2%)       2 (4%)                   
      Aorta, Adventitia, Inflammation, Chronic                                                                                      
        Active                                                                                             1 (2%)                   
   Heart                                              (53)         (53)         (52)         (53)         (53)         (52)         
      Cardiomyopathy                                  15 (28%)     12 (23%)     19 (37%)     13 (25%)     18 (34%)     24 (46%)     
      Hemorrhage                                       2 (4%)                                                                       
      Infiltration Cellular, Mononuclear Cell                                                                           1 (2%)      
      Inflammation                                     1 (2%)                    1 (2%)       1 (2%)                                
      Mineralization                                                                          1 (2%)       1 (2%)       1 (2%)      
      Artery, Inflammation, Chronic Active                                                                 1 (2%)       2 (4%)      
      Epicardium, Inflammation                                      1 (2%)                                              1 (2%)      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (53)         (53)         (53)         (52)         (53)         (53)         
      Angiectasis                                     31 (58%)     37 (70%)     30 (57%)     33 (63%)     27 (51%)     35 (66%)     
      Atrophy                                          3 (6%)                                 1 (2%)                    4 (8%)      
      Degeneration, Cystic                             4 (8%)      17 (32%)     14 (26%)     18 (35%)     12 (23%)     14 (26%)     
      Hematopoietic Cell Proliferation                                           1 (2%)                    1 (2%)       1 (2%)      
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    4                                                              
                                                                                                                                   
NTP Experiment-Test: 96007-05         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                             TOXIC EQUIVALENCY FACTOR EVALUATION(PECDF)                        Date: 09/30/03    
Route: GAVAGE                                                                                                     Time: 11:22:49    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG/KG      6 NG/KG      20 NG/KG     44 NG/KG     92 NG/KG     200             
                                                                                                                    NG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
ENDOCRINE SYSTEM - CONT                                                                                                             
      Hemorrhage                                       1 (2%)                                 1 (2%)                                
      Hyperplasia                                      8 (15%)     10 (19%)     10 (19%)      7 (13%)     10 (19%)     11 (21%)     
      Hypertrophy                                     42 (79%)     43 (81%)     43 (81%)     46 (88%)     44 (83%)     45 (85%)     
      Necrosis                                         4 (8%)                    2 (4%)                    2 (4%)                   
      Vacuolization Cytoplasmic                        9 (17%)     13 (25%)     14 (26%)      7 (13%)     17 (32%)      9 (17%)     
   Adrenal Medulla                                    (53)         (53)         (53)         (52)         (53)         (53)         
      Hyperplasia                                     11 (21%)     12 (23%)     14 (26%)     14 (27%)      7 (13%)     10 (19%)     
   Islets, Pancreatic                                 (53)         (53)         (53)         (52)         (52)         (52)         
      Hyperplasia                                                                                                       2 (4%)      
   Parathyroid Gland                                  (49)         (51)         (44)         (51)         (49)         (49)         
      Hyperplasia                                                   1 (2%)       1 (2%)                    1 (2%)       1 (2%)      
      Hypertrophy                                                   1 (2%)                                                          
   Pituitary Gland                                    (53)         (53)         (53)         (53)         (53)         (53)         
      Angiectasis                                     20 (38%)     21 (40%)     20 (38%)     13 (25%)     12 (23%)     14 (26%)     
      Atrophy                                          1 (2%)                                                                       
      Cyst                                             2 (4%)                                 1 (2%)       1 (2%)       1 (2%)      
      Cytoplasmic Alteration                           1 (2%)                                              1 (2%)                   
      Vacuolization Cytoplasmic                        2 (4%)       2 (4%)       1 (2%)                                             
      Pars Distalis, Hyperplasia                      22 (42%)     16 (30%)     14 (26%)     11 (21%)     15 (28%)     19 (36%)     
      Pars Intermedia, Hyperplasia                     1 (2%)                                                                       
      Rathke's Cleft, Pars Intermedia, Hyperplasia                                                         1 (2%)                   
   Thyroid Gland                                      (53)         (53)         (51)         (53)         (51)         (51)         
      Inflammation                                                               1 (2%)                                             
      C-Cell, Hyperplasia                             15 (28%)     16 (30%)      9 (18%)     13 (25%)      9 (18%)     11 (22%)     
      Follicle, Cyst                                   1 (2%)                                 1 (2%)       1 (2%)                   
      Follicular Cell, Hypertrophy                     7 (13%)     13 (25%)     24 (47%)     24 (45%)     24 (47%)     22 (43%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Clitoral Gland                                     (53)         (51)         (53)         (53)         (50)         (53)         
      Hyperplasia, Squamous                                                      1 (2%)                                             
      Inflammation                                    52 (98%)     47 (92%)     46 (87%)     51 (96%)     47 (94%)     47 (89%)     
      Duct, Cyst                                      40 (75%)     37 (73%)     34 (64%)     41 (77%)     44 (88%)     40 (75%)     
   Ovary                                              (53)         (53)         (53)         (52)         (52)         (53)         
      Atrophy                                         43 (81%)     40 (75%)     38 (72%)     43 (83%)     45 (87%)     45 (85%)     
      Cyst                                            11 (21%)     18 (34%)     20 (38%)     17 (33%)     18 (35%)     13 (25%)     
      Fibrosis                                                                                1 (2%)                                
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    5                                                              
                                                                                                                                   
NTP Experiment-Test: 96007-05         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                             TOXIC EQUIVALENCY FACTOR EVALUATION(PECDF)                        Date: 09/30/03    
Route: GAVAGE                                                                                                     Time: 11:22:49    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG/KG      6 NG/KG      20 NG/KG     44 NG/KG     92 NG/KG     200             
                                                                                                                    NG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
GENITAL SYSTEM - CONT                                                                                                               
      Inflammation, Chronic Active                     1 (2%)                                              1 (2%)       1 (2%)      
   Oviduct                                            (1)                                                 (1)                       
      Cyst                                             1 (100%)                                                                     
      Inflammation, Chronic Active                                                                         1 (100%)                 
   Uterus                                             (53)         (53)         (53)         (52)         (52)         (53)         
      Adenomyosis                                      1 (2%)                                 1 (2%)       1 (2%)                   
      Cyst                                                          1 (2%)                                 1 (2%)                   
      Hemorrhage                                                                                           1 (2%)       2 (4%)      
      Inflammation, Chronic Active                                  5 (9%)       3 (6%)       3 (6%)       4 (8%)       3 (6%)      
      Inflammation, Suppurative                        3 (6%)       6 (11%)      1 (2%)       7 (13%)      3 (6%)       4 (8%)      
      Metaplasia, Squamous                            17 (32%)     25 (47%)     21 (40%)     36 (69%)     31 (60%)     35 (66%)     
      Ulcer                                                                                   1 (2%)       3 (6%)       1 (2%)      
      Cervix, Cyst                                                                                                      1 (2%)      
      Endometrium, Hyperplasia, Cystic                31 (58%)     29 (55%)     29 (55%)     33 (63%)     39 (75%)     37 (70%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Bone Marrow                                        (53)         (53)         (53)         (53)         (53)         (53)         
      Atrophy                                                                    2 (4%)                                             
      Hyperplasia                                     38 (72%)     32 (60%)     37 (70%)     35 (66%)     42 (79%)     41 (77%)     
      Hyperplasia, Reticulum Cell                                                             1 (2%)                                
   Lymph Node                                         (5)          (4)          (4)          (4)          (3)          (7)          
      Hyperplasia, Plasma Cell                                                                                          1 (14%)     
      Iliac, Ectasia                                                1 (25%)                                                         
      Lumbar, Ectasia                                  2 (40%)      1 (25%)                                1 (33%)                  
      Lumbar, Hemorrhage                               2 (40%)      1 (25%)                                                         
      Lumbar, Hyperplasia, Histiocytic                                                        1 (25%)      1 (33%)                  
      Lumbar, Hyperplasia, Plasma Cell                              1 (25%)      1 (25%)      1 (25%)                   1 (14%)     
      Mediastinal, Ectasia                                                                                 2 (67%)      2 (29%)     
      Mediastinal, Hemorrhage                                                    1 (25%)                                1 (14%)     
      Mediastinal, Hyperplasia, Lymphoid                                         1 (25%)                                            
      Mediastinal, Hyperplasia, Plasma Cell                         1 (25%)                   1 (25%)      1 (33%)      2 (29%)     
      Popliteal, Ectasia                               1 (20%)                                                                      
   Lymph Node, Mandibular                             (53)         (53)         (51)         (53)         (51)         (51)         
      Congestion                                                                 1 (2%)                                             
      Ectasia                                                       1 (2%)       2 (4%)       1 (2%)       1 (2%)       1 (2%)      
      Hyperplasia, Histiocytic                                      1 (2%)                                                          
      Hyperplasia, Lymphoid                                                                   1 (2%)                    1 (2%)      
      Hyperplasia, Plasma Cell                        38 (72%)     40 (75%)     38 (75%)     31 (58%)     30 (59%)     29 (57%)     
   Lymph Node, Mesenteric                             (53)         (53)         (53)         (52)         (52)         (53)         
      Atrophy                                                                                 1 (2%)                                
      Hemorrhage                                       1 (2%)                    1 (2%)                                 1 (2%)      
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    6                                                              
                                                                                                                                   
NTP Experiment-Test: 96007-05         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                             TOXIC EQUIVALENCY FACTOR EVALUATION(PECDF)                        Date: 09/30/03    
Route: GAVAGE                                                                                                     Time: 11:22:49    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG/KG      6 NG/KG      20 NG/KG     44 NG/KG     92 NG/KG     200             
                                                                                                                    NG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
HEMATOPOIETIC SYSTEM - CONT                                                                                                         
      Hyperplasia, Histiocytic                                                                                          1 (2%)      
      Hyperplasia, Lymphoid                                         1 (2%)       1 (2%)                                 1 (2%)      
      Hyperplasia, Plasma Cell                                      1 (2%)                                              1 (2%)      
   Spleen                                             (53)         (53)         (53)         (52)         (52)         (51)         
      Accessory Spleen                                 1 (2%)                    1 (2%)                                             
      Congestion                                                    1 (2%)                                 1 (2%)                   
      Hematopoietic Cell Proliferation                49 (92%)     49 (92%)     48 (91%)     51 (98%)     46 (88%)     50 (98%)     
      Hemorrhage                                                    1 (2%)                                                          
      Infarct                                                                    1 (2%)                                             
      Necrosis                                                      1 (2%)                                                          
      Pigmentation                                    52 (98%)     45 (85%)     50 (94%)     48 (92%)     49 (94%)     51 (100%)    
      Lymphatic, Angiectasis                                                     1 (2%)                                             
      Lymphoid Follicle, Atrophy                       7 (13%)      8 (15%)      7 (13%)      6 (12%)     12 (23%)      4 (8%)      
      Red Pulp, Atrophy                                2 (4%)                                                                       
      Red Pulp, Hyperplasia                                         1 (2%)                                                          
   Thymus                                             (53)         (49)         (50)         (52)         (49)         (51)         
      Atrophy                                         43 (81%)     36 (73%)     36 (72%)     44 (85%)     39 (80%)     48 (94%)     
      Hemorrhage                                       1 (2%)                    1 (2%)                    1 (2%)       1 (2%)      
      Hyperplasia, Lymphoid                                                      1 (2%)                                             
      Inflammation                                                  1 (2%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Mammary Gland                                      (53)         (53)         (53)         (53)         (53)         (53)         
      Cyst                                             1 (2%)       2 (4%)                    5 (9%)       4 (8%)       3 (6%)      
      Hyperplasia                                     33 (62%)     29 (55%)     26 (49%)     20 (38%)     20 (38%)     17 (32%)     
      Inflammation, Granulomatous                      2 (4%)       4 (8%)       3 (6%)       4 (8%)       4 (8%)       3 (6%)      
   Skin                                               (53)         (53)         (53)         (53)         (53)         (53)         
      Inflammation                                     2 (4%)       1 (2%)                                                          
      Ulcer                                            2 (4%)       1 (2%)                                                          
      Conjunctiva, Inflammation                                                                                         1 (2%)      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   Brain                                              (53)         (53)         (53)         (53)         (53)         (53)         
      Edema                                                                                   1 (2%)                                
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    7                                                              
                                                                                                                                   
NTP Experiment-Test: 96007-05         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                             TOXIC EQUIVALENCY FACTOR EVALUATION(PECDF)                        Date: 09/30/03    
Route: GAVAGE                                                                                                     Time: 11:22:49    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG/KG      6 NG/KG      20 NG/KG     44 NG/KG     92 NG/KG     200             
                                                                                                                    NG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
NERVOUS SYSTEM - CONT                                                                                                               
      Gliosis                                                                                 1 (2%)                                
      Hemorrhage                                       1 (2%)                                                           1 (2%)      
      Hydrocephalus                                    1 (2%)                                 1 (2%)                    1 (2%)      
   Peripheral Nerve                                                                          (1)                       (1)          
      Radicular Neuropathy                                                                                              1 (100%)    
   Spinal Cord                                                                               (1)                       (1)          
      Degeneration                                                                                                      1 (100%)    
      Hemorrhage                                                                              1 (100%)                              
      Necrosis                                                                                1 (100%)                              
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (53)         (53)         (53)         (53)         (53)         (52)         
      Edema                                                                                                1 (2%)                   
      Hemorrhage                                                                                           1 (2%)                   
      Infiltration Cellular, Histiocyte               44 (83%)     44 (83%)     40 (75%)     40 (75%)     41 (77%)     36 (69%)     
      Inflammation                                     5 (9%)       8 (15%)      7 (13%)      6 (11%)      7 (13%)      8 (15%)     
      Metaplasia, Squamous                                                                    2 (4%)       4 (8%)       3 (6%)      
      Mineralization                                                                          1 (2%)       1 (2%)                   
      Alveolar Epithelium, Hyperplasia                14 (26%)     17 (32%)     12 (23%)     20 (38%)      8 (15%)      3 (6%)      
      Alveolar Epithelium, Metaplasia, Bronchiolar     5 (9%)       6 (11%)      5 (9%)       9 (17%)     23 (43%)     28 (54%)     
      Alveolus, Metaplasia, Squamous                                             1 (2%)                                             
   Nose                                               (53)         (53)         (53)         (53)         (53)         (53)         
      Inflammation                                     8 (15%)      3 (6%)       8 (15%)     11 (21%)      7 (13%)      6 (11%)     
      Mineralization                                   1 (2%)                                                                       
      Olfactory Epithelium, Metaplasia                                           1 (2%)                                             
      Respiratory Epithelium, Hyperplasia              1 (2%)       1 (2%)       2 (4%)       1 (2%)       6 (11%)      3 (6%)      
      Respiratory Epithelium, Metaplasia                                                                                1 (2%)      
      Septum, Inflammation                             1 (2%)       2 (4%)       3 (6%)       2 (4%)       5 (9%)       3 (6%)      
      Squamous Epithelium, Hyperplasia                 1 (2%)       1 (2%)       1 (2%)                                             
   Trachea                                            (53)         (53)         (52)         (53)         (53)         (53)         
      Inflammation                                                                                         1 (2%)       1 (2%)      
      Artery, Peritracheal Tissue, Inflammation,                                                                                    
         Chronic Active                                                                                                 1 (2%)      
      Peritracheal Tissue, Inflammation                             1 (2%)       2 (4%)       1 (2%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   Eye                                                (53)         (53)         (52)         (53)         (52)         (52)         
      Hemorrhage                                                    1 (2%)                                                          
      Inflammation                                                  1 (2%)                                 1 (2%)                   
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    8                                                              
                                                                                                                                   
NTP Experiment-Test: 96007-05         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                             TOXIC EQUIVALENCY FACTOR EVALUATION(PECDF)                        Date: 09/30/03    
Route: GAVAGE                                                                                                     Time: 11:22:49    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG/KG      6 NG/KG      20 NG/KG     44 NG/KG     92 NG/KG     200             
                                                                                                                    NG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
SPECIAL SENSES SYSTEM - CONT                                                                                                        
      Cornea, Inflammation                                                                                              1 (2%)      
      Lens, Degeneration                                            1 (2%)                                                          
      Retina, Atrophy                                                            1 (2%)                                             
      Retina, Degeneration                                          1 (2%)                                                          
   Harderian Gland                                    (53)         (53)         (53)         (53)         (52)         (52)         
      Inflammation                                    16 (30%)      9 (17%)     10 (19%)     13 (25%)      8 (15%)      6 (12%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (53)         (53)         (53)         (52)         (53)         (53)         
      Accumulation, Hyaline Droplet                                 1 (2%)                                                          
      Calculus Micro Observation Only                  5 (9%)       2 (4%)       4 (8%)       1 (2%)       2 (4%)       3 (6%)      
      Cyst                                                                                    1 (2%)       2 (4%)       1 (2%)      
      Fibrosis                                                                                                          1 (2%)      
      Hemorrhage                                                                                           1 (2%)                   
      Inflammation, Chronic Active                                                                         1 (2%)       1 (2%)      
      Inflammation, Suppurative                        2 (4%)       1 (2%)       1 (2%)       3 (6%)       2 (4%)       2 (4%)      
      Mineralization                                  37 (70%)     45 (85%)     42 (79%)     43 (83%)     43 (81%)     31 (58%)     
      Necrosis                                                                                             2 (4%)                   
      Nephropathy                                     34 (64%)     39 (74%)     35 (66%)     42 (81%)     36 (68%)     45 (85%)     
      Pigmentation                                     2 (4%)                                                                       
      Artery, Inflammation, Chronic Active                                                    1 (2%)       1 (2%)                   
      Capsule, Hemorrhage                              1 (2%)                                                                       
      Pelvis, Dilatation                                            1 (2%)                                 2 (4%)       1 (2%)      
      Pelvis, Inflammation                             1 (2%)       1 (2%)                                 5 (9%)       1 (2%)      
      Renal Tubule, Dilatation                                                   1 (2%)                                             
      Renal Tubule, Hyperplasia                                                  1 (2%)                                             
      Renal Tubule, Necrosis                                        1 (2%)                                                          
      Renal Tubule, Nephropathy                                                                                         1 (2%)      
      Transitional Epithelium, Hyperplasia             2 (4%)       2 (4%)       1 (2%)       2 (4%)       6 (11%)      5 (9%)      
   Urinary Bladder                                    (53)         (52)         (53)         (53)         (51)         (53)         
      Infiltration Cellular, Lymphoid                                                                                   1 (2%)      
      Inflammation                                     2 (4%)       3 (6%)       1 (2%)       1 (2%)       6 (12%)      1 (2%)      
      Transitional Epithelium, Hyperplasia                          1 (2%)                                 4 (8%)       4 (8%)      
      Transitional Epithelium, Metaplasia, Squamous                                                        1 (2%)                   
                                                                                                                                    
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page    9                                                              
                                                                                                                                   
NTP Experiment-Test: 96007-05         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                             TOXIC EQUIVALENCY FACTOR EVALUATION(PECDF)                        Date: 09/30/03    
Route: GAVAGE                                                                                                     Time: 11:22:49    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                200 NG/                                                                          
                                                   KG STOP                                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially In Study                          50                                                                            
  Early Deaths                                                                                                                      
    Moribund Sacrifice                                25                                                                            
    Natural Death                                     10                                                                            
  Survivors                                                                                                                         
    Terminal Sacrifice                                15                                                                            
                                                                                                                                    
  Animals Examined Microscopically                    50                                                                            
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Intestine Large, Rectum                            (50)                                                                          
      Parasite Metazoan                                2 (4%)                                                                       
   Liver                                              (50)                                                                          
      Angiectasis                                      1 (2%)                                                                       
      Basophilic Focus                                 9 (18%)                                                                      
      Basophilic Focus, Multiple                       4 (8%)                                                                       
      Cholangiofibrosis                                3 (6%)                                                                       
      Clear Cell Focus                                 4 (8%)                                                                       
      Clear Cell Focus, Multiple                       2 (4%)                                                                       
      Degeneration, Cystic                             1 (2%)                                                                       
      Eosinophilic Focus                               8 (16%)                                                                      
      Eosinophilic Focus, Multiple                    14 (28%)                                                                      
      Fatty Change, Diffuse                            6 (12%)                                                                      
      Fatty Change, Focal                              7 (14%)                                                                      
      Hematopoietic Cell Proliferation                31 (62%)                                                                      
      Hepatodiaphragmatic Nodule                       1 (2%)                                                                       
      Inflammation                                    48 (96%)                                                                      
      Mixed Cell Focus                                 5 (10%)                                                                      
      Mixed Cell Focus, Multiple                      19 (38%)                                                                      
      Necrosis                                        11 (22%)                                                                      
      Pigmentation                                    48 (96%)                                                                      
      Toxic Hepatopathy                                9 (18%)                                                                      
      Bile Duct, Cyst                                  2 (4%)                                                                       
      Bile Duct, Fibrosis                              1 (2%)                                                                       
      Bile Duct, Hyperplasia                           1 (2%)                                                                       
      Centrilobular, Degeneration                      7 (14%)                                                                      
      Hepatocyte, Hypertrophy                         14 (28%)                                                                      
      Hepatocyte, Multinucleated                      25 (50%)                                                                      
      Oval Cell, Hyperplasia                           3 (6%)                                                                       
   Mesentery                                          (2)                                                                           
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page   10                                                              
                                                                                                                                   
NTP Experiment-Test: 96007-05         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                             TOXIC EQUIVALENCY FACTOR EVALUATION(PECDF)                        Date: 09/30/03    
Route: GAVAGE                                                                                                     Time: 11:22:49    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                200 NG/                                                                          
                                                   KG STOP                                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
ALIMENTARY SYSTEM - CONT                                                                                                            
      Inflammation, Chronic Active                     1 (50%)                                                                      
      Necrosis                                         1 (50%)                                                                      
   Oral Mucosa                                        (50)                                                                          
      Gingival, Hyperplasia, Squamous                 14 (28%)                                                                      
   Pancreas                                           (49)                                                                          
      Acinus, Vacuolization Cytoplasmic                2 (4%)                                                                       
      Artery, Inflammation, Chronic Active             1 (2%)                                                                       
   Stomach, Forestomach                               (50)                                                                          
      Erosion                                          1 (2%)                                                                       
      Hyperkeratosis                                   1 (2%)                                                                       
      Hyperplasia, Squamous                            5 (10%)                                                                      
      Inflammation                                     1 (2%)                                                                       
      Ulcer                                            1 (2%)                                                                       
   Stomach, Glandular                                 (50)                                                                          
      Mineralization                                   3 (6%)                                                                       
   Tooth                                              (24)                                                                          
      Peridontal Tissue, Inflammation                 24 (100%)                                                                     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                              (50)                                                                          
      Cardiomyopathy                                  13 (26%)                                                                      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (48)                                                                          
      Angiectasis                                     29 (60%)                                                                      
      Degeneration, Cystic                            12 (25%)                                                                      
      Hyperplasia                                      7 (15%)                                                                      
      Hypertrophy                                     36 (75%)                                                                      
      Necrosis                                         3 (6%)                                                                       
      Vacuolization Cytoplasmic                       10 (21%)                                                                      
      Bilateral, Inflammation, Chronic Active          1 (2%)                                                                       
   Adrenal Medulla                                    (48)                                                                          
      Hyperplasia                                      7 (15%)                                                                      
   Parathyroid Gland                                  (47)                                                                          
      Fibrosis                                         1 (2%)                                                                       
   Pituitary Gland                                    (49)                                                                          
      Angiectasis                                     13 (27%)                                                                      
      Cyst                                             1 (2%)                                                                       
      Cytoplasmic Alteration                           2 (4%)                                                                       
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page   11                                                              
                                                                                                                                   
NTP Experiment-Test: 96007-05         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                             TOXIC EQUIVALENCY FACTOR EVALUATION(PECDF)                        Date: 09/30/03    
Route: GAVAGE                                                                                                     Time: 11:22:49    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                200 NG/                                                                          
                                                   KG STOP                                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
ENDOCRINE SYSTEM - CONT                                                                                                             
      Vacuolization Cytoplasmic                        2 (4%)                                                                       
      Pars Distalis, Hyperplasia                      19 (39%)                                                                      
   Thyroid Gland                                      (48)                                                                          
      C-Cell, Hyperplasia                             15 (31%)                                                                      
      Follicular Cell, Hypertrophy                    23 (48%)                                                                      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Clitoral Gland                                     (50)                                                                          
      Inflammation                                    48 (96%)                                                                      
      Duct, Cyst                                      39 (78%)                                                                      
   Ovary                                              (47)                                                                          
      Atrophy                                         39 (83%)                                                                      
      Cyst                                            12 (26%)                                                                      
   Uterus                                             (49)                                                                          
      Congestion                                       1 (2%)                                                                       
      Hemorrhage                                       1 (2%)                                                                       
      Inflammation, Chronic Active                     7 (14%)                                                                      
      Inflammation, Suppurative                        3 (6%)                                                                       
      Metaplasia, Squamous                            28 (57%)                                                                      
      Endometrium, Hyperplasia, Cystic                35 (71%)                                                                      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Bone Marrow                                        (50)                                                                          
      Hyperplasia                                     43 (86%)                                                                      
   Lymph Node                                         (3)                                                                           
      Iliac, Ectasia                                   1 (33%)                                                                      
      Iliac, Hyperplasia, Plasma Cell                  1 (33%)                                                                      
      Lumbar, Ectasia                                  1 (33%)                                                                      
      Lumbar, Hyperplasia, Plasma Cell                 1 (33%)                                                                      
      Renal, Ectasia                                   1 (33%)                                                                      
      Renal, Hyperplasia, Plasma Cell                  1 (33%)                                                                      
   Lymph Node, Mandibular                             (49)                                                                          
      Ectasia                                          1 (2%)                                                                       
      Hyperplasia, Lymphoid                            1 (2%)                                                                       
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page   12                                                              
                                                                                                                                   
NTP Experiment-Test: 96007-05         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                             TOXIC EQUIVALENCY FACTOR EVALUATION(PECDF)                        Date: 09/30/03    
Route: GAVAGE                                                                                                     Time: 11:22:49    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                200 NG/                                                                          
                                                   KG STOP                                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
HEMATOPOIETIC SYSTEM - CONT                                                                                                         
      Hyperplasia, Plasma Cell                        29 (59%)                                                                      
   Spleen                                             (49)                                                                          
      Hematopoietic Cell Proliferation                49 (100%)                                                                     
      Pigmentation                                    48 (98%)                                                                      
      Lymphoid Follicle, Atrophy                       2 (4%)                                                                       
   Thymus                                             (49)                                                                          
      Atrophy                                         44 (90%)                                                                      
      Hemorrhage                                       1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Mammary Gland                                      (50)                                                                          
      Cyst                                             3 (6%)                                                                       
      Hyperplasia                                     19 (38%)                                                                      
      Inflammation                                     1 (2%)                                                                       
      Inflammation, Granulomatous                      1 (2%)                                                                       
   Skin                                               (50)                                                                          
      Hyperkeratosis                                   1 (2%)                                                                       
      Lip, Inflammation, Chronic Active                1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   Bone                                               (50)                                                                          
      Osteopetrosis                                    1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   Brain                                              (49)                                                                          
      Mineralization                                   1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (50)                                                                          
      Congestion                                       1 (2%)                                                                       
      Hemorrhage                                       2 (4%)                                                                       
      Infiltration Cellular, Histiocyte               30 (60%)                                                                      
      Inflammation                                     5 (10%)                                                                      
      Metaplasia, Squamous                             1 (2%)                                                                       
      Mineralization                                   1 (2%)                                                                       
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page   13                                                              
                                                                                                                                   
NTP Experiment-Test: 96007-05         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                             TOXIC EQUIVALENCY FACTOR EVALUATION(PECDF)                        Date: 09/30/03    
Route: GAVAGE                                                                                                     Time: 11:22:49    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                200 NG/                                                                          
                                                   KG STOP                                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
RESPIRATORY SYSTEM - CONT                                                                                                           
      Alveolar Epithelium, Hyperplasia                 6 (12%)                                                                      
      Alveolar Epithelium, Metaplasia, Bronchiolar     7 (14%)                                                                      
   Nose                                               (50)                                                                          
      Inflammation                                     7 (14%)                                                                      
      Nasolacrimal Duct, Inflammation                  1 (2%)                                                                       
      Respiratory Epithelium, Hyperplasia              2 (4%)                                                                       
   Trachea                                            (50)                                                                          
      Inflammation                                     1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   Eye                                                (49)                                                                          
      Retina, Atrophy                                  1 (2%)                                                                       
   Harderian Gland                                    (49)                                                                          
      Inflammation                                     6 (12%)                                                                      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (48)                                                                          
      Accumulation, Hyaline Droplet                    3 (6%)                                                                       
      Calculus Micro Observation Only                  1 (2%)                                                                       
      Infarct                                          1 (2%)                                                                       
      Inflammation                                     1 (2%)                                                                       
      Inflammation, Suppurative                        2 (4%)                                                                       
      Mineralization                                  41 (85%)                                                                      
      Nephropathy                                     35 (73%)                                                                      
      Pelvis, Dilatation                               1 (2%)                                                                       
      Pelvis, Inflammation                             1 (2%)                                                                       
      Transitional Epithelium, Hyperplasia             3 (6%)                                                                       
   Urinary Bladder                                    (50)                                                                          
      Inflammation                                     2 (4%)                                                                       
      Transitional Epithelium, Hyperplasia             3 (6%)                                                                       
                                                                                                                                    
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   14                                                              
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------